LDN MCAS - Integrative Functional Medicine and LDN Community

ldn

One Medication, Three Conditions: Why LDN Is Not a Silver Bullet for Long COVID, ME/CFS, and MCAS

Endorphin Depletion, Immune Dysregulation, and the Limits of Pharmacological Optimism Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Introduction: The Allure of a Universal Solution It is tempting to look at Low Dose Naltrexone (LDN) and see a single medication capable of addressing

LDN MCAS

Low-Dose Naltrexone in the MCAS/POTS/hEDS Trifecta:Clinical Teaching Points for Ultra-Sensitive Clients

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician July 2026 ⚠ IMPORTANT MEDICAL DISCLAIMER This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Low-dose naltrexone (LDN) is not FDA-approved for mast cell activation

LDN MCAS

When LDN Crashes the System: Ultra-Low-Dose Strategies for MCAS, POTS, and the Hypersensitive Client

Introduction: The Client Who Cannot Tolerate What Should Help In integrative medicine, we are trained to believe that low-dose naltrexone (LDN) is gentle. Compared to full-dose naltrexone at 50 mg, a dose of 0.1 mg or even 1 mg seems trivially small. The standard clinical teaching is